Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Director | February 18, 2026 | February 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date February 18, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 241,026 |
Reported balance
After 2026-02-18 transaction · row 1
1 source rowRow 1 · 2026-02-18 · Grant · Acquired 48,828 · Balance 241,026 F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CARDINAL HEALTH INC
Report date August 15, 2019 · Filed August 19, 2019
Section 16 reporting ended · disclosed 2019-08-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 61,387 |
Reported balance
After 2019-08-15 transaction · row 1
1 source rowRow 1 · 2019-08-15 · Tax withholding · Disposed 6,854 · Balance 61,387 F1: Represents withholding of shares to satisfy tax withholding obligations of the reporting person in connection with the vesting of 16,534 restricted share units. F2: Reflects closing price on prior business day. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents withholding of shares to satisfy tax withholding obligations of the reporting person in connection with the vesting of 16,534 restricted share units.
F2: Reflects closing price on prior business day.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 17:27 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 48,828 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000055 · form4.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,026 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2027. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:41 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 49,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003210 · form4.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,198 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2026. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 17:20 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 51,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004305 · form4.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,623 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2025. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 17:46 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 65,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004882 · form4.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,603 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2024. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 19:02 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 20,547 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-004808 · form4.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,866 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2023. Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:52 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001661181-21-000044 · edgar.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,319 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over three years beginning May 7, 2021. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 12:53 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | Tax withholdingCommon Shares | 6,854 | $42.41 | $290,678.14 |
DisclosureSEC source: 0000721371-19-000081 · wf-form4_156621916251247.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · CEO, Medical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,387 F1 · kind: Represents withholding of shares to satisfy tax withholding obligations of the reporting person in connection with the vesting of 16,534 restricted share units. F2 · price: Reflects closing price on prior business day. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 13:36 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | Tax withholdingCommon Shares | 4,411 | $55.50 | $244,810.50 |
DisclosureSEC source: 0000721371-19-000014 · wf-form4_155058335193416.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · CEO, Medical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,241 F1 · kind: Represents withholding of shares to satisfy tax withholding obligations of the reporting person in connection with the vesting of 14,684 restricted share units. F2 · price: Reflects closing price on prior business day. Read SEC document |
| August 20, 2018 Filed Aug 21, 2018 20:08 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | SaleCommon Shares | 2,890 | $51.95 | $150,135.50 |
DisclosureSEC source: 0000721371-18-000075 · wf-form4_153488205621061.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · CEO, Medical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,652 Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 21:15 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | Tax withholdingCommon Shares | 3,387 | $50.17 | $169,925.79 |
DisclosureSEC source: 0000721371-18-000073 · wf-form4_153445411265412.xml · nonDerivative · entry 2 Giacomin Jon L · CIK 0001623254 · CEO, Medical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,542 F2 · kind: Represents withholding of shares to satisfy tax withholding obligations of the reporting person in connection with the vesting of 11,343 RSUs. F3 · price: Reflects closing price on prior business day. Read SEC document |
| August 15, 2018 Filed Aug 16, 2018 21:15 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | GrantCommon Shares | 23,881 | $0.00 | $0.00 |
DisclosureSEC source: 0000721371-18-000073 · wf-form4_153445411265412.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · CEO, Medical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,929 F1 · kind: Grant of restricted share units ("RSUs") that vest in three equal annual installments beginning on August 15, 2019. Read SEC document |
| February 20, 2018 Filed Feb 20, 2018 22:54 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | SaleCommon Shares | 2,271 | $69.12 | $156,971.52 |
DisclosureSEC source: 0000721371-18-000027 · wf-form4_151916722984024.xml · nonDerivative · entry 3 Giacomin Jon L · CIK 0001623254 · CEO, Medical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,048 F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.03 to $69.20, inclusive. Read SEC document |
| February 20, 2018 Filed Feb 20, 2018 22:54 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | SaleCommon Shares | 5,724 | $68.65 | $392,952.60 |
DisclosureSEC source: 0000721371-18-000027 · wf-form4_151916722984024.xml · nonDerivative · entry 2 Giacomin Jon L · CIK 0001623254 · CEO, Medical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,319 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.01 to $69.00, inclusive. The reporting person undertakes to provide to Cardinal Health, Inc., any security holder of Cardinal Health, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 22:54 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | GrantCommon Shares | 14,684 | $0.00 | $0.00 |
DisclosureSEC source: 0000721371-18-000027 · wf-form4_151916722984024.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · CEO, Medical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,043 F1 · kind: Grant of restricted share units that vest on February 15, 2019. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 20:35 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | Tax withholdingCommon Shares | 845 | $67.46 | $57,003.70 |
DisclosureSEC source: 0000721371-17-000114 · wf-form4_150576674460731.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · CEO, Pharmaceutical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,359 F1 · kind: Represents withholding of shares to satisfy tax withholding obligations of the reporting person in connection with the vesting of 1,779 restricted share units. F2 · price: Reflects closing price on prior business day. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:36 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | GrantEmployee Stock Option (right to buy) · Derivative | 70,102 | $0.00 Strike: $66.43 | $0.00 |
DisclosureSEC source: 0000721371-17-000098 · wf-form4_150300577154679.xml · derivative · entry 3 Giacomin Jon L · CIK 0001623254 · CEO, Pharmaceutical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,102 Underlying: Common Shares · 70,102 shares Expires 2027-08-15 F4 · derivative.exercise_date: Stock option vests in three equal annual installments beginning on August 15, 2018. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:36 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | Tax withholdingCommon Shares | 8,243 | $66.76 | $550,302.68 |
DisclosureSEC source: 0000721371-17-000098 · wf-form4_150300577154679.xml · nonDerivative · entry 2 Giacomin Jon L · CIK 0001623254 · CEO, Pharmaceutical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,204 F2 · kind: Represents withholding of shares to satisfy tax withholding obligations of the reporting person in connection with the vesting of 7,645 RSUs and 10,976 performance share units. F3 · price: Reflects closing price on prior business day. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 21:36 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | GrantCommon Shares | 14,301 | $0.00 | $0.00 |
DisclosureSEC source: 0000721371-17-000098 · wf-form4_150300577154679.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · CEO, Pharmaceutical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,447 F1 · kind: Grant of restricted share units ("RSUs") that vest in three equal annual installments beginning on August 15, 2018. Read SEC document |
| August 08, 2017 Filed Aug 9, 2017 20:23 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | GrantCommon Shares | 10,976 | $0.00 | $0.00 |
DisclosureSEC source: 0000721371-17-000068 · wf-form4_150231022236886.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · CEO, Pharmaceutical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,146 F1 · kind: Reflects performance share units that will settle on August 15, 2017. Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:59 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 23,270 | $41.60 Strike: $41.60 | $968,032.00 |
DisclosureSEC source: 0000721371-17-000035 · wf-form4_149488191986209.xml · derivative · entry 3 Giacomin Jon L · CIK 0001623254 · CEO, Pharmaceutical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 23,270 shares Expires 2021-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, representing a right to purchase a total of 23,270 shares, vested and became exercisable in three equal annual installments beginning on August 15, 2012. Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:59 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | SaleCommon Shares | 23,270 | $72.87 | $1,695,684.90 |
DisclosureSEC source: 0000721371-17-000035 · wf-form4_149488191986209.xml · nonDerivative · entry 2 Giacomin Jon L · CIK 0001623254 · CEO, Pharmaceutical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,170 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.81 to $72.91, inclusive. The reporting person undertakes to provide to Cardinal Health, Inc., any security holder of Cardinal Health, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4. Read SEC document |
| May 12, 2017 Filed May 15, 2017 20:59 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | Exercise / conversionCommon Shares | 23,270 | $41.60 | $968,032.00 |
DisclosureSEC source: 0000721371-17-000035 · wf-form4_149488191986209.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · CEO, Pharmaceutical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 12:25 UTC | CARDINAL HEALTH INC CAH · Entity 3014 | Tax withholdingCommon Shares | 845 | $75.26 | $63,594.70 |
DisclosureSEC source: 0000721371-16-000314 · wf-form4_147428793264130.xml · nonDerivative · entry 1 Giacomin Jon L · CIK 0001623254 · CEO, Pharmaceutical Segment 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,170 F1 · kind: Represents withholding of shares to satisfy tax withholding obligations of the reporting person in connection with the vesting of 1,779 restricted share units. F2 · price: Reflects closing price on prior business day. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.